PubRank

Jean-Louis Fischel

Author PubWeight™ 9.88‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine. Clin Cancer Res 2003 1.06
2 Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition. Eur J Cancer 2008 0.85
3 Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation. Mol Cancer Ther 2005 0.84
4 Emerging molecular targeted therapies in the treatment of head and neck cancer. Expert Opin Emerg Drugs 2009 0.83
5 Epidermal growth factor receptor/angiogenesis dual targeting: preclinical experience. Curr Opin Oncol 2006 0.81
6 Gefitinib-trastuzumab combination on hormone-refractory prostate cancer xenograft. Eur J Cancer 2005 0.80
7 Antitumor activity of cetuximab associated with the taxotere-cisplatin-fluorouracil (TPF) combination on an orthotopic head and neck cancer model. Oral Oncol 2011 0.78
8 The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts. Oral Oncol 2011 0.78
9 Tapered dose versus constant drug exposure to anti-EGFR drugs on head-and-neck cancer xenografts. A comparison between cetuximab and gefitinib. Oral Oncol 2010 0.78
10 Overexpression of cortactin in head and neck squamous cell carcinomas can be uncoupled from augmented EGF receptor expression. Acta Oncol 2008 0.78
11 Combination of docetaxel and vandetanib in docetaxel-sensitive or resistant PC3 cell line. Urol Oncol 2011 0.78
12 Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical study. Invest New Drugs 2012 0.77
13 Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines. Urol Oncol 2012 0.75
14 Dual HER 1-2 targeting of hormone-refractory prostate cancer by ZD1839 and trastuzumab. Eur J Cancer 2004 0.75
15 Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants. Fundam Clin Pharmacol 2011 0.75